"Serotonin Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
| Descriptor ID |
D012702
|
| MeSH Number(s) |
D27.505.519.625.850.850 D27.505.696.577.850.850
|
| Concept/Terms |
Serotonin Antagonists- Serotonin Antagonists
- 5-Hydroxytryptamine Antagonists
- 5 Hydroxytryptamine Antagonists
- Antagonists, 5-HT
- Antagonists, 5 HT
- Serotonin Receptor Blockers
- Blockers, Serotonin Receptor
- Receptor Blockers, Serotonin
- Antagonists, Serotonin
- Antiserotonergic Agents
- Agents, Antiserotonergic
- Serotonin Blockaders
- Blockaders, Serotonin
- Serotonin Receptor Antagonists
- Antagonists, Serotonin Receptor
- Receptor Antagonists, Serotonin
- 5-HT Antagonists
- 5 HT Antagonists
- Antagonists, 5-Hydroxytryptamine
- Antagonists, 5 Hydroxytryptamine
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Antagonists".
This graph shows the total number of publications written about "Serotonin Antagonists" by people in this website by year, and whether "Serotonin Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 4 | 4 |
| 2015 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Antagonists" by people in Profiles.
-
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019 01; 44(2):390-398.
-
The Role of ERK1/2 Activation in Sarpogrelate-Mediated Neuroprotection. Invest Ophthalmol Vis Sci. 2018 01 01; 59(1):462-471.
-
The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatr. 2015 Jun; 166(6):1449-54.e1.
-
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14.
-
Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT(1A) receptor-adenylyl cyclase axis. FASEB J. 2014 Apr; 28(4):1735-44.
-
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer. 2013 Apr 01; 119(7):1428-36.
-
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer. 2012 Oct; 20(10):2583-8.
-
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66.
-
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.
-
Agents that reverse UV-Induced immune suppression and photocarcinogenesis affect DNA repair. J Invest Dermatol. 2010 May; 130(5):1428-37.